Source comparison
Thymosin Alpha-1 Long Term Studies: Trial Comparison
Italian Multicenter (2003) 60 months Chronic HBV (n=1,009) HBeAg seroconversion 51% seroconversion by month 60 vs 23% control Longest continuous thymosin alpha-1 dataset; response continues past standard treatment windows Chinese HCC Cohort (2018) 36 months Po
This comparison does not assign a generated winner or score.
- Italian Multicenter (2003)
- 60 months
- Chronic HBV (n=1,009)
- HBeAg seroconversion
- 51% seroconversion by month 60 vs 23% control
- Longest continuous thymosin alpha-1 dataset; response continues past standard treatment windows
- Chinese HCC Cohort (2018)
- 36 months
- Post-resection HCC (n=302)
- Recurrence-free survival
- 31% improvement vs observation
- Effect size increases after 18 months rather than plateauing
- Shanghai Jiao Tong PK Study (2021)
- 24 months
- Healthy volunteers (n=64)
- Serum half-life stability
- 2.1hr half-life unchanged through 700+ doses
- No pharmacokinetic drift or metabolic adaptation
- Journal of Clinical Immunology Pooled Analysis (2018)
- 12–48 months
- Multiple conditions (n=847)
- Safety profile
- 0.4% serious adverse events
- Rate equivalent to placebo; no cumulative toxicity signals